All In Biotech

Drug Trial Radar · NCT04544449

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Patients With Primary Progressive Multiple Sclerosis.

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 985 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

985

Actual

Start

Oct 26, 2020

Primary completion

Sep 17, 2025

Study completion Jul 21, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study.

Conditions

  • Multiple Sclerosis, Primary Progressive

Interventions

  • FenebrutinibDrug

    Participants will receive fenebrutinib.

  • OcrelizumabDrug

    Participants will receive ocrelizumab.

  • Placebo matched to ocrelizumabDrug

    Participants will receive ocrelizumab-matching placebo.

  • Placebo matched to fenebrutinibDrug

    Participants will receive fenebrutinib-matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Onset of Composite 12-Week Confirmed Disability Progression (cCDP12)Time frame: Minimum of 120 weeks

Locations

190 sites in 28 countries. Site status is shown where the registry gives one.

  • Alabama Neurology Associates

    Homewood, Alabama

  • Sutter East Bay Medical Foundation

    Berkeley, California

  • Fullerton Neurology and Headache Center

    Fullerton, California

  • Palo Alto Medical Foundation Research Center

    Sunnyvale, California

  • University of Colorado Denver

    Aurora, Colorado

  • Yale University School Of Medicine

    Fairfield, Connecticut

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Neurology Associates PA

    Maitland, Florida

  • Neurological Services of Orlando

    Orlando, Florida

  • University of South Florida

    Tampa, Florida

  • Josephson Wallack Munshower Neurology PC

    Indianapolis, Indiana

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Johns Hopkins University School Of Medicine

    Baltimore, Maryland

  • Dragonfly Research, LLC

    Wellesley, Massachusetts

  • Wayne State University

    Detroit, Michigan

  • Minneapolis Clinic of Neurology

    Golden Valley, Minnesota

  • Washington University

    St Louis, Missouri

  • Cleveland Clinic Lou Ruvo

    Las Vegas, Nevada

  • Hackensack U Med Ctr

    Hackensack, New Jersey

  • Barnabas Health Ambulatory Care Center

    Livingston, New Jersey

  • Jersey Shore University Medical Centre

    Neptune City, New Jersey

  • Rutgers New Jersey Medical School

    Newark, New Jersey

  • Holy Name Hospital

    Teaneck, New Jersey

  • Dent Neurological Institute

    Amherst, New York

  • Columbia University Medical Center

    New York, New York

  • University of Rochester

    Rochester, New York

  • Stony Brook University Medical Center

    Stony Brook, New York

  • SUNY Upstate Medical University

    Syracuse, New York

  • Atrium Health Neurosciences Institute ? Charlotte

    Charlotte, North Carolina

  • Raleigh Neurology Associates

    Raleigh, North Carolina

  • Miami Valley Hospital South

    Centerville, Ohio

  • UC Health, LLC.

    Cincinnati, Ohio

  • OhioHealth Riverside Methodist Hospital

    Columbus, Ohio

  • Providence Brain and Spine Institute

    Portland, Oregon

  • Neurology Clinic PC

    Cordova, Tennessee

  • Hope Neurology

    Knoxville, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Uni of Texas Health Science Center At Houston

    Houston, Texas

  • Texas Institute for Neurological Disorders

    Sherman, Texas

  • Evergreen MS Center

    Kirkland, Washington

Showing 40 of 190 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.